Lisdexamfetamine dimesylate (Tyvense®)

Assessment Status Rapid Review Complete
Drug Lisdexamfetamine dimesylate
Brand Tyvense®
Indication For Attention Deficit Hyperactivity Disorder in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate.
Assessment Process
Rapid review commissioned 09/02/2013
Rapid review completed 28/02/2013
Rapid review outcome Full Pharmacoeconomic Assessment Not Recommended